GFACX
Price
$61.91
Change
-$1.33 (-2.10%)
Updated
Sep 6 closing price
MNRGX
Price
$38.68
Change
-$0.69 (-1.75%)
Updated
Sep 6 closing price
Ad is loading...

GFACX vs MNRGX

Header iconGFACX vs MNRGX Comparison
Open Charts GFACX vs MNRGXBanner chart's image
American Funds Growth Fund of Amer C
Price$61.91
Change-$1.33 (-2.10%)
VolumeN/A
CapitalizationN/A
Manor Growth
Price$38.68
Change-$0.69 (-1.75%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
GFACX vs MNRGX Comparison Chart
Loading...
VS
GFACX vs. MNRGX commentary
Sep 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GFACX is a Buy and MNRGX is a Buy.

FUNDAMENTALS
Fundamentals
GFACX has more cash in the bank: 270B vs. MNRGX (15.7M). MNRGX pays higher dividends than GFACX: MNRGX (0.21) vs GFACX (0.00). GFACX was incepted earlier than MNRGX: GFACX (24 years) vs MNRGX (25 years). GFACX is a more actively managed with annual turnover of: 31.00 vs. MNRGX (12.87). GFACX has a lower initial minimum investment than MNRGX: GFACX (250) vs MNRGX (1000). GFACX annual gain was more profitable for investors over the last year : 16.44 vs. MNRGX (14.57). MNRGX return over 5 years is better than : 53.61 vs. GFACX (38.56).
GFACXMNRGXGFACX / MNRGX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence24 years25 years-
Gain YTD14.98211.027136%
Front LoadN/AN/A-
Min. Initial Investment250100025%
Min. Initial Investment IRAN/AN/A-
Net Assets270B15.7M1,719,745%
Annual Yield % from dividends0.000.21-
Returns for 1 year16.4414.57113%
Returns for 3 years-11.087.59-146%
Returns for 5 years38.5653.6172%
Returns for 10 years42.46103.8141%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KW11.040.03
+0.27%
Kennedy-Wilson Holdings
CTVA55.11-0.39
-0.70%
Corteva
FIVN29.58-0.24
-0.80%
Five9
VEV0.14N/A
-1.68%
Vicinity Motor Corp
ADAP1.11-0.05
-4.31%
Adaptimmune Therapeutics plc